Redefining Treatment Approaches in Advanced HCC

Richard S. Finn, MD, leads a panel of experts in a discussion around key updates from the 2021 ASCO GI virtual meeting, and a review of the rapidly evolving landscape for unresectable advanced hepatocellular carcinoma.

A panel of experts discuss practical considerations for TACE in patients with unresectable BCLC stage B HCC, as well as define TACE-refractoriness and what to do if a patient fails treatment.

Amit G. Singal, MD, MS, leads a review of recent data around the outcomes of systemic therapy for patients with BCLC stage B HCC.

An in-depth discussion about the role of TACE in combination with systemic therapies for the treatment of HCC.

Experts discuss recent data surrounding emerging combinations of TACE plus systemic therapies for patients with BCLC stage B or C HCC.

A discussion about the recent data from trials that looked at atezolizumab-bevacizumab for the treatment of advanced HCC, and its role as the new standard of care.

Laura M. Kulik, MD, leads a discussion about personal experiences using atezolizumab-bevacizumab and whether clinical trial data reflect real-world experience.

Experts in the field of HCC consider second and third lines of therapy after a patient’s disease state progresses after frontline atezolizumab-bevacizumab.

Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.

An examination of the use of second-line therapies after atezolizumab-bevacizumab, and the role of TKIs for the treatment of advanced HCC.

A summary of updates that explore ongoing data from various frontline combinations in unresectable HCC.

Experts discuss emerging data in immunotherapy combination approaches for the treatment of advanced HCC.

A summary of ongoing clinical data that explore the use of frontline single agent immunotherapy in advanced HCC.

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

A panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.